Now available BYOOVIZ®

BYOOVIZ (ranibizumab-nuna) is biosimilar to LUCENTIS (ranibizumabinjection).

BYOOVIZ, a vascular endothelial growth factor (VEGF) inhibitor, is indicated for the treatment of patients with:

- Neovascular (Wet) Age-Related Macular Degeneration (AMD)

- Macular Edema Following Retinal Vein Occlusion (RVO)

- Myopic Choroidal Neovascularization (mCNV)